Dr. Reddy's Laboratories Limited (RDY) 주식 분석

회사 개요

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical entity with a global footprint spanning North America, Europe, India, Russia, and international markets. The company functions within the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, indicating its focus on producing both specialized and generic medicinal products. As of the latest data, the organization employs 27,811 individuals and holds a market capitalization of $11.05B with a trailing twelve-month revenue of $345.83B. These valuation and revenue figures suggest that Dr. Reddy's Laboratories Limited is a significant player in the pharmaceutical landscape, possessing substantial operational scale and a large workforce dedicated to its global drug manufacturing and distribution activities.

재무 건전성

The company reported a trailing twelve-month revenue of $345.83B, generating a net income of $56.59B and an EBITDA of $84.79B. The substantial difference between the revenue figure and the net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately 83.6% of total revenue before reaching the bottom line. Dr. Reddy's Laboratories Limited generated free cash flow of $13.47B, which provides the organization with significant financial flexibility to fund capital expenditures, pursue acquisitions, or manage working capital requirements without relying on external financing. The company maintains a gross margin of 55.2%, reflecting strong pricing power or cost efficiencies in its production of specialty and generic drugs. Furthermore, the operating margin stands at 16.4%, while the profit margin is identical at 16.4%, indicating that the company's operational costs are fully captured within the profit margin calculation in this dataset. In terms of liquidity and leverage, the company holds $82.59B in cash against total debt of $67.73B, resulting in a debt-to-equity ratio of 18.03, which suggests a highly leveraged balance sheet relative to equity, though the high cash position mitigates immediate solvency risks. The current ratio of 1.88 indicates that the company has sufficient current assets to cover its current liabilities nearly twice over, pointing to robust short-term liquidity. Additionally, the Return on Equity is 16.1% and the Return on Assets is 8.0%, metrics that reveal how effectively management utilizes shareholder capital and total assets to generate profits.

밸류에이션 평가

The trailing twelve-month P/E ratio is 18.14, while the forward P/E is 23.73. The difference between these two metrics implies that the market expects earnings to decline in the future, as the forward valuation is higher than the historical average despite the anticipated lower earnings per share. The price-to-book ratio is 2.77, indicating that the market values the company at a premium of roughly 177% over its book value, which can reflect intangible assets, brand value, or future growth expectations not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.03 and an EV/EBITDA of -0.01. The extremely low price-to-sales ratio and negative EV/EBITDA suggest a potential disconnect between current market price and earnings generation, possibly due to one-time charges or specific accounting adjustments affecting the valuation multiples. The stock has traded between a 52-week high of $16.17 and a 52-week low of $12.26. Given the forward P/E context, the current valuation multiple expansion relative to the trailing P/E suggests investors are pricing in a specific earnings trajectory that may alter the stock's position within this range. The stock exhibits a beta of 0.30, which indicates that the stock's price volatility is significantly lower than the broader market, moving with less intensity than the overall index.

Growth & Income

Regarding growth metrics, the company experienced a revenue growth of 4.4% year-over-year, while earnings growth was -14.3% year-over-year. This divergence implies that the company's earnings are growing slower than its revenue, specifically contracting in this period, which suggests rising costs or one-time expenses are impacting profitability more severely than top-line sales. The company offers a dividend yield of 0.7% with a payout ratio of 11.8%. This low payout ratio indicates that the company retains the majority of its earnings rather than distributing them, suggesting a sustainable dividend policy that prioritizes reinvestment or balance sheet strengthening over maximizing current shareholder cash returns. Consequently, the company's strategy appears to focus on internal growth and operational expansion rather than aggressive dividend distribution. Overall, the growth and income profile presents a scenario of modest revenue expansion coupled with a contraction in earnings, supported by a highly conservative dividend policy that offers minimal but stable income to shareholders.